At the archive date, PFIZER INC was expected to release its Q3 2026 10-Q filing on November 2, 2026. Last quarter: Pfizer's Q2 FY2026 revenue grew 3% to $15.0 billion, but a $3 billion impairment and legal charge drove a net loss of $248 million, even as operating cash flow surged 97% year-over-year.
EPS Estimate
$0.77
Revenue Estimate
$16.11B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the PFE page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Total revenues increased 3% operationally in Q2 2026, driven by Eliquis (+19% operational), Padcev (+23%), and Vyndaqel family (+8%), offset by COVID-19 product declines. Excluding Comirnaty and Paxlovid, revenues rose 5% operationally.
Pfizer announced expansions to its Realigning Our Cost Base program, adding $1.0 billion in net cost savings to reach $6.7 billion through 2029, and its Manufacturing Optimization program, adding $1.5 billion in savings to reach $3.0 billion through 2029.
In May 2026, Pfizer entered a strategic licensing and collaboration agreement with Innovent for 12 cancer medicines, including a $650 million upfront payment and up to $9.85 billion in milestone payments, closing in July 2026.
Revenue
$15.03B
+2.60% YoY
EPS (Diluted)
-$0.04
-107.84% YoY
Add PFE to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.